The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

Abstract Background Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14 months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel multimodal treatment approach we combined the checkpoint kinase 1 (Chk1) in...

Full description

Bibliographic Details
Published in:	Journal of Experimental & Clinical Cancer Research
Main Authors:	Ina Patties, Sonja Kallendrusch, Lisa Böhme, Eva Kendzia, Henry Oppermann, Frank Gaunitz, Rolf-Dieter Kortmann, Annegret Glasow
Format:	Article
Language:	English
Published:	BMC 2019-10-01
Subjects:	Glioblastoma Chk1 inhibitor SAR-020106 Decitabine Irradiation Temozolomide
Online Access:	http://link.springer.com/article/10.1186/s13046-019-1434-2

Similar Items

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage
by: Anell Fernandez, et al.
Published: (2025-05-01)

Editorial: Regulation and dysfunction of CSK and CHK
by: Shudong Zhu, et al.
Published: (2023-07-01)

Functions and inhibitors of CHK1 in cancer therapy
by: Kailong Jiang, et al.
Published: (2024-06-01)

Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
by: Luis I. Toledo, et al.
Published: (2011-08-01)

Immunomodulatory Effects by Photodynamic Treatment of Glioblastoma Cells In Vitro
by: Friederike Rothe, et al.
Published: (2022-05-01)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
by: Seungyoun Kim, et al.
Published: (2021-12-01)

AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR–CHK2 interaction and prostate cancer survival
by: Huy Q Ta, et al.
Published: (2020-06-01)

Hairpin-bisulfite sequencing of cells exposed to decitabine documents the process of DNA demethylation
by: Issam M Mayyas, et al.
Published: (2021-11-01)

Acute appendicitis in acute leukemia and the potential role of decitabine in the critically ill patient
by: Deepti Warad, et al.
Published: (2015-01-01)

A Novel Cognition of Decitabine: Insights into Immunomodulation and Antiviral Effects
by: Ji Xiao, et al.
Published: (2022-03-01)

Therapeutic effect of folic acid combined with decitabine on diabetic mice
by: Gang Du, et al.
Published: (2023-11-01)

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
by: Timothy Budden, et al.
Published: (2018-01-01)

CHK2 Promotes Metabolic Stress-Induced Autophagy through ULK1 Phosphorylation
by: Ran Guo, et al.
Published: (2022-06-01)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
by: Xiaoshuang Kong, et al.
Published: (2023-04-01)

A drug repurposing screen identifies decitabine as an HSV-1 antiviral
by: Laura Bautista, et al.
Published: (2024-11-01)

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma
by: Angélique Bruyer, et al.
Published: (2023-12-01)

Temozolomide in treatment resistant prolactinomas
by: V. N. Shree, et al.
Published: (2018-08-01)

Decitabine regulates the resistance of HCC to sorafenib through demethylation
by: Miao Zhang, et al.
Published: (2025-07-01)

Mechanism of action of decitabine in treating acute lymphoblastic leukemia
by: Xiaohui Gao, et al.
Published: (2025-07-01)

A novel role for the ROS-ATM-Chk2 axis mediated metabolic and cell cycle reprogramming in the M1 macrophage polarization
by: Chunlu Li, et al.
Published: (2024-04-01)

Sustained CHK2 activity, but not ATM activity, is critical to maintain a G1 arrest after DNA damage in untransformed cells
by: Iraia García-Santisteban, et al.
Published: (2021-02-01)

Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors
by: Clare E. Murray, et al.
Published: (2024-10-01)

Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance
by: Laure David, et al.
Published: (2017-09-01)

Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1
by: Li Tao, et al.
Published: (2024-03-01)

Low‐dose decitabine plus venetoclax as post‐transplant maintenance for high‐risk myeloid malignancies
by: Katherine Parks, et al.
Published: (2024-06-01)

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine
by: Zay Yar Oo, et al.
Published: (2019-07-01)

Enhanced anti-tumor effects by combination of tucatinib and radiation in HER2-overexpressing human cancer cell lines
by: Lukas Amrell, et al.
Published: (2024-08-01)

Decitabine promotes the differentiation of poorly differentiated gastric cancer cells and enhances the sensitivity of NK cell cytotoxicity via TNF-α
by: Man Lv, et al.
Published: (2025-04-01)

Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children
by: Na Zhang, et al.
Published: (2024-05-01)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
by: Brian A. Jonas, et al.
Published: (2023-01-01)

Decitabine combined with arsenic trioxide inhibits proliferation and promotes apoptosis of acute myeloid leukemia cell lines
by: LIU Yue, CAO Yang, GU Weiying, SHANG Limei, LIU Yan
Published: (2023-04-01)

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report
by: Ankur Sheel, et al.
Published: (2023-01-01)

Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection
by: Lydia E. Hainley, et al.
Published: (2021-07-01)

Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance
by: Young Keun Hwang, et al.
Published: (2024-08-01)

Enhanced FOXO1 expression as a predictor of decitabine response and prolonged survival in high-risk myelodysplastic syndrome
by: Hong Liu, et al.
Published: (2025-12-01)

Inhibition of Melanoma Cell Growth by Salvianolic Acid A through CHK2-CDC25A Pathway Modulation
by: Xiao-Yan Pu, et al.
Published: (2024-06-01)

Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia
by: Yan Wu, et al.
Published: (2024-11-01)

Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells
by: Lanke Lin, et al.
Published: (2023-03-01)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
by: Hui Liu, et al.
Published: (2023-07-01)

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells
by: Sonia Abou Najem, et al.
Published: (2019-11-01)